BMS-663068 - CAS 864953-29-7
Catalog number: 864953-29-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C25H26N7O8P
Molecular Weight:
583.49
COA:
Inquire
Targets:
HIV
Description:
BMS-663068 is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection. It is a prodrug for BMS-626529, which binds to the viral envelope glycoprotein gp120 and interferes with attachment of the virus to the cellular CD4 receptor.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
Fostemsavir
MSDS:
Inquire
1.Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
Landry I1, Zhu L1, Abu Tarif M1, Hruska M1, Sadler BM2, Pitsiu M3, Joshi S4, Hanna GJ1, Lataillade M4, Boulton DW1, Bertz RJ5. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2782-9. doi: 10.1128/AAC.02503-15. Print 2016 May.
BMS-663068 is an oral prodrug of the HIV-1 attachment inhibitor BMS-626529, which prevents viral attachment to host CD4(+) T cells by binding to HIV-1 gp120. To guide dose selection for the phase 3 program, pharmacokinetic/pharmacodynamic modeling was performed using data from two phase 2 studies with HIV-1-infected subjects (n = 244). BMS-626529 population pharmacokinetics were described by a two-compartment model with first-order elimination from the central compartment, zero-order release of prodrug from the extended-release formulation into a hypothetical absorption compartment, and first-order absorption into the central compartment. The covariates of BMS-663068 formulation type, lean body mass, baseline CD8(+) T-cell percentage, and ritonavir coadministration were found to be significant contributors to intersubject variability. Exposure-response analyses showed a relationship between the loge-transformed concentration at the end of a dosing interval (Ctau) normalized for the protein binding-adjusted BMS-626529 half-maximal (50%) inhibitory concentration (PBAIC50) and the change in the HIV-1 RNA level from the baseline level after 7 days of BMS-663068 monotherapy.
2.Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Zhu L1, Hruska M2, Hwang C2, Shah V2, Furlong M2, Hanna GJ2, Bertz R2, Landry IS2. Antimicrob Agents Chemother. 2015 Jul;59(7):3816-22. doi: 10.1128/AAC.04914-14. Epub 2015 Apr 13.
BMS-663068 is a prodrug of BMS-626529, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4(+) T cells. This open-label, multiple-dose, four-sequence, crossover study addressed potential two-way drug-drug interactions following coadministration of BMS-663068 (BMS-626529 is a CYP3A4 substrate), atazanavir (ATV), and ritonavir (RTV) (ATV and RTV are CYP3A4 inhibitors). Thirty-six healthy subjects were randomized 1:1:1:1 to receive one of four treatment sequences with three consecutive treatments: BMS-663068 at 600 mg twice daily (BID), BMS-663068 at 600 mg BID plus RTV at 100 mg once daily (QD), ATV at 300 mg QD plus RTV at 100 mg QD (RTV-boosted ATV [ATV/r]), or BMS-663068 at 600 mg BID plus ATV at 300 mg QD plus RTV at 100 mg QD. Compared with the results obtained by administration of BMS-663068 alone, coadministration of BMS-663068 with ATV/r increased the BMS-626529 maximum concentration in plasma (Cmax) and the area under the concentration-time curve in one dosing interval (AUCtau) by 68% and 54%, respectively.
3.Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Lalezari JP1, Latiff GH2, Brinson C3, Echevarría J4, Treviño-Pérez S5, Bogner JR6, Thompson M7, Fourie J8, Sussmann Pena OA9, Mendo Urbina FC10, Martins M11, Diaconescu IG12, Stock DA13, Joshi SR13, Hanna GJ14, Lataillade M13; AI438011 study team. Lancet HIV. 2015 Oct;2(10):e427-37. doi: 10.1016/S2352-3018(15)00177-0. Epub 2015 Sep 1.
BACKGROUND: BMS-663068 is an oral prodrug of BMS-626529, an attachment inhibitor that binds to HIV-1 gp120, blocking viral attachment to host CD4 cells. AI438011 is an ongoing trial investigating the efficacy, safety, and dose-response of BMS-663068 in treatment-experienced, HIV-1-infected patients. Herein we present the results of the primary analysis.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HIV Products


CAS 357263-13-9 BMS-378806

BMS-378806
(CAS: 357263-13-9)

BMS-378806 selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.

CAS 106362-32-7 Peptide T

Peptide T
(CAS: 106362-32-7)

Peptide T is an HIV entry inhibitor that acts by blocking chemokine-5 receptors (CCR5), currently under clinical trials for the treatment of HIV-related neurolo...

CAS 202138-50-9 Tenofovir Disoproxil Fumarate

Tenofovir Disoproxil Fumarate
(CAS: 202138-50-9)

Tenofovir Disoproxil Fumarate belongs to a class of antiretroviral drugs, it inhibits the activity of HIV reverse transcriptase by competing with the natural su...

CAS 134624-73-0 Stavudine sodium

Stavudine sodium
(CAS: 134624-73-0)

Stavudine sodium is a dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. Stavudine sodium is an analog of thymi...

BMS-488043
(CAS: 452296-83-2)

BMS-488043 is a small-molecule HIV fusion inhibitor.

CAS 957890-42-5 HIV-1 integrase inhibitor 2

HIV-1 integrase inhibitor 2
(CAS: 957890-42-5)

HIV-1 integrase inhibitor 2 is useful for anti-HIV, which can target HIV-1 integrase and depress the activity in the treatment of HIV infection, AIDS, and other...

CAS 333352-59-3 NBD-557

NBD-557
(CAS: 333352-59-3)

NBD-557 is a N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide analog, a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitors th...

CAS 7481-89-2 Zalcitabine

Zalcitabine
(CAS: 7481-89-2)

Zalcitabine is a nucleoside analog HIV reverse transcriptase inhibitor (NARTI).

CAS 729607-74-3 BMS-707035

BMS-707035
(CAS: 729607-74-3)

BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM.

CAS 333353-44-9 NBD-556

NBD-556
(CAS: 333353-44-9)

NBD-556 is small molecule mimetic of CD4. NBD-556 recognizes the HIV-1 envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding. The C...

CAS 701213-36-7 BMS-626529

BMS-626529
(CAS: 701213-36-7)

BMS-626529 is a member of the new drug class of HIV-1 attachment inhibitors currently in development. BMS-663068 is the phosphonooxymethyl prodrug of BMS-626529...

CAS 20633-67-4 Calycosin-7-O-beta-D-glucoside

Calycosin-7-O-beta-D-glucoside
(CAS: 20633-67-4)

Calycosin-7-O-β-D-glucoside, a melanin biosynthesis inhibitor, is isolated from the methanol extract of astragalus. It showed scavenging activity to DPPH radica...

CAS 518048-05-0 Raltegravir

Raltegravir
(CAS: 518048-05-0)

Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM, respectively.

CAS 431980-38-0 RN-18

RN-18
(CAS: 431980-38-0)

RN-18, a selective inhibitor of virion infectivity factor (Vif) APOBEC interactions and HIV-1 replication (IC50= 6 μM in nonpermissive H9 cells), antagonizes Vi...

CAS 3056-17-5 Stavudine (d4T)

Stavudine (d4T)
(CAS: 3056-17-5)

Stavudine (d4T) is a nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV.

CAS 62956-48-3 Gomisin G

Gomisin G
(CAS: 62956-48-3)

Gomisin G, carboxylic acid with additional oxygen functions, exhibited the most potent anti-HIV activity with EC50 and therapeutic index (TI) values of 0.006 mi...

CAS 376348-65-1 Maraviroc

Maraviroc
(CAS: 376348-65-1)

Selective CCR5 antagonist

CAS 192725-17-0 Lopinavir

Lopinavir
(CAS: 192725-17-0)

Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM.

CAS 1051375-16-6 Dolutegravir (GSK1349572)

Dolutegravir (GSK1349572)
(CAS: 1051375-16-6)

Dolutegravir (GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM, modest activity against raltegravir-resistant signature mutants Y1...

CAS 198904-31-3 Atazanavir

Atazanavir
(CAS: 198904-31-3)

Atazanavir is a novel and potent azapeptide protease inhibitor that specifically inhibits the human immunodeficiency virus type 1 (HIV-1) protease enzyme with i...

Chemical Structure

CAS 864953-29-7 BMS-663068

Quick Inquiry

Verification code

Featured Items